Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit

被引:65
作者
Gröning, R
Berntgen, M
Georgarakis, M
机构
[1] Aristotelian Univ Salonika, Sect Pharmaceut Technol, GR-54006 Salonika, Greece
[2] Univ Munster, Inst Pharmaceut Technol, D-4400 Munster, Germany
关键词
sustained release acyclovir; gastric residence time; magnetic tablets; extracorporal magnet; gastroretentive dosage forms; bioavailability;
D O I
10.1016/S0939-6411(98)00052-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present investigations peroral acyclovir depot tablets with internal magnets were developed. An extracorporal magnet was used to prolong the gastric residence times of the dosage forms and to influence the duration of absorption of acyclovir. The magnetic depot tablets contained 200 mg acyclovir. In a three-way cross-over in vivo study with five healthy male subjects, the plasma concentration-time profiles of acyclovir were determined. The acyclovir plasma concentrations following peroral administration of magnetic depot tablets in the presence and absence of an extracorporal magnet were determined. A commercially available immediate release preparation was used as a reference preparation. In the presence of an extracorporal magnet which was placed in the stomach region, the plasma concentrations of acyclovir were significantly higher after 7, 8, 10 and 12 h (P < 0.05, U-test, Wilcoxon, Mann-Whitney). The mean area under the plasma concentration-time-curve (AUC(0-24h)), in the presence of the extracorporal magnet was 2802.7 ngh/ml. Without the extracorporal magnet a mean AUC(0-24h) of 1598.8 ngh/ml was achieved. Computer simulations were carried out to show the influence of the gastric residence time of acyclovir depot preparations on the plasma concentration-time profiles of acyclovir. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:285 / 291
页数:7
相关论文
共 22 条
[1]  
ERNI W, 1987, European Neurology, V27, P21, DOI 10.1159/000116171
[2]   EFFECT OF MAGNETICALLY CONTROLLED GASTRIC RESIDENCE OF SUSTAINED-RELEASE TABLETS ON BIOAVAILABILITY OF ACETAMINOPHEN [J].
FUJIMORI, J ;
MACHIDA, Y ;
TANAKA, S ;
NAGAI, T .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 119 (01) :47-55
[3]  
FUJIMORI J, 1994, STP PHARMA SCI, V4, P425
[4]  
GARDNER C, 1986, Patent No. 202159
[5]  
GRONING R, 1984, PHARM IND, V46, P88
[7]  
Groning R, 1996, PHARMAZIE, V51, P328
[8]  
Groning R, 1996, EUR J PHARM BIOPHARM, V42, P25
[9]   ORAL DOSAGE FORMS WITH CONTROLLED GASTROINTESTINAL TRANSIT [J].
GRONING, R ;
HEUN, G .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1984, 10 (04) :527-539
[10]  
GRONING R, 1989, PHARM ACTA HELV, V64, P71